Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17015749rdf:typepubmed:Citationlld:pubmed
pubmed-article:17015749lifeskim:mentionsumls-concept:C0162638lld:lifeskim
pubmed-article:17015749lifeskim:mentionsumls-concept:C0178539lld:lifeskim
pubmed-article:17015749lifeskim:mentionsumls-concept:C0021467lld:lifeskim
pubmed-article:17015749lifeskim:mentionsumls-concept:C2699153lld:lifeskim
pubmed-article:17015749lifeskim:mentionsumls-concept:C1269955lld:lifeskim
pubmed-article:17015749lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:17015749lifeskim:mentionsumls-concept:C0754623lld:lifeskim
pubmed-article:17015749lifeskim:mentionsumls-concept:C1999216lld:lifeskim
pubmed-article:17015749lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:17015749lifeskim:mentionsumls-concept:C0279023lld:lifeskim
pubmed-article:17015749lifeskim:mentionsumls-concept:C1522538lld:lifeskim
pubmed-article:17015749lifeskim:mentionsumls-concept:C1879547lld:lifeskim
pubmed-article:17015749lifeskim:mentionsumls-concept:C0664750lld:lifeskim
pubmed-article:17015749lifeskim:mentionsumls-concept:C0301625lld:lifeskim
pubmed-article:17015749pubmed:issue8lld:pubmed
pubmed-article:17015749pubmed:dateCreated2006-10-3lld:pubmed
pubmed-article:17015749pubmed:abstractTextDeguelin, a constituent of the bark of the African plant Mundulea sericea (Leguminosae), exhibits antiproliferative and anticarcinogenic activities through a mechanism that is not well understood. Because various steps in carcinogenesis are regulated by NF-kappaB, we postulated that the activity of deguelin is mediated through this transcription factor. We found that deguelin suppressed NF-kappaB activation induced by carcinogens, tumor promoters, growth factors, and inflammatory stimuli. This suppression was not cell-type specific, because NF-kappaB activation was suppressed in both lymphoid and epithelial cells. Moreover, constitutive NF-kappaB activation was also blocked by deguelin. The suppression of TNF-induced NF-kappaB activation by deguelin occurred through the inhibition of the activation of IkappaBalpha kinase, leading to sequential suppression of IkappaBalpha phosphorylation, IkappaBalpha degradation, p65 phosphorylation, p65 nuclear translocation, and NF-kappaB-dependent reporter gene expression. Deguelin also suppressed the NF-kappaB reporter activity induced by TNFR1, TNFR-associated death domain, TNFR-associated factor 2, and IkappaBalpha kinase, but not that induced by p65. The inhibition of NF-kappaB activation thereby led to the down-regulation of gene products involved in cell survival, proliferation, and invasion. Suppression of these gene products by deguelin enhanced the apoptosis induced by TNF and chemotherapeutic agents and suppressed TNF-induced cellular invasion. Our results demonstrate that deguelin inhibits the NF-kappaB activation pathway, which may explain its role in the suppression of carcinogenesis and cellular proliferation.lld:pubmed
pubmed-article:17015749pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17015749pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17015749pubmed:languageenglld:pubmed
pubmed-article:17015749pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17015749pubmed:citationSubsetAIMlld:pubmed
pubmed-article:17015749pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17015749pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17015749pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17015749pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17015749pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17015749pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17015749pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17015749pubmed:statusMEDLINElld:pubmed
pubmed-article:17015749pubmed:monthOctlld:pubmed
pubmed-article:17015749pubmed:issn0022-1767lld:pubmed
pubmed-article:17015749pubmed:authorpubmed-author:AggarwalBhara...lld:pubmed
pubmed-article:17015749pubmed:authorpubmed-author:ShishodiaShis...lld:pubmed
pubmed-article:17015749pubmed:authorpubmed-author:AhnKwang...lld:pubmed
pubmed-article:17015749pubmed:authorpubmed-author:SethiGautamGlld:pubmed
pubmed-article:17015749pubmed:authorpubmed-author:KunnumakkaraA...lld:pubmed
pubmed-article:17015749pubmed:authorpubmed-author:NairAsha SASlld:pubmed
pubmed-article:17015749pubmed:issnTypePrintlld:pubmed
pubmed-article:17015749pubmed:day15lld:pubmed
pubmed-article:17015749pubmed:volume177lld:pubmed
pubmed-article:17015749pubmed:ownerNLMlld:pubmed
pubmed-article:17015749pubmed:authorsCompleteYlld:pubmed
pubmed-article:17015749pubmed:pagination5612-22lld:pubmed
pubmed-article:17015749pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:17015749pubmed:meshHeadingpubmed-meshheading:17015749...lld:pubmed
pubmed-article:17015749pubmed:meshHeadingpubmed-meshheading:17015749...lld:pubmed
pubmed-article:17015749pubmed:meshHeadingpubmed-meshheading:17015749...lld:pubmed
pubmed-article:17015749pubmed:meshHeadingpubmed-meshheading:17015749...lld:pubmed
pubmed-article:17015749pubmed:meshHeadingpubmed-meshheading:17015749...lld:pubmed
pubmed-article:17015749pubmed:meshHeadingpubmed-meshheading:17015749...lld:pubmed
pubmed-article:17015749pubmed:meshHeadingpubmed-meshheading:17015749...lld:pubmed
pubmed-article:17015749pubmed:meshHeadingpubmed-meshheading:17015749...lld:pubmed
pubmed-article:17015749pubmed:meshHeadingpubmed-meshheading:17015749...lld:pubmed
pubmed-article:17015749pubmed:meshHeadingpubmed-meshheading:17015749...lld:pubmed
pubmed-article:17015749pubmed:meshHeadingpubmed-meshheading:17015749...lld:pubmed
pubmed-article:17015749pubmed:meshHeadingpubmed-meshheading:17015749...lld:pubmed
pubmed-article:17015749pubmed:meshHeadingpubmed-meshheading:17015749...lld:pubmed
pubmed-article:17015749pubmed:meshHeadingpubmed-meshheading:17015749...lld:pubmed
pubmed-article:17015749pubmed:meshHeadingpubmed-meshheading:17015749...lld:pubmed
pubmed-article:17015749pubmed:year2006lld:pubmed
pubmed-article:17015749pubmed:articleTitleDeguelin, an Akt inhibitor, suppresses IkappaBalpha kinase activation leading to suppression of NF-kappaB-regulated gene expression, potentiation of apoptosis, and inhibition of cellular invasion.lld:pubmed
pubmed-article:17015749pubmed:affiliationDepartment of Experimental Therapeutics, Cytokine Research Laboratory, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.lld:pubmed
pubmed-article:17015749pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17015749pubmed:publicationTypeResearch Support, U.S. Gov't, Non-P.H.S.lld:pubmed
pubmed-article:17015749pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:17015749pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17015749lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17015749lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17015749lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17015749lld:pubmed